Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shandong Luye Pharmaceutical Co. Ltd. maintains 1 pending office action within the Biotechnology & Pharmaceuticals sector. This 1 pending office action is currently assigned to 1 distinct examiner and 1 distinct art unit. The concentration of the company's prosecution into a single matter indicates a highly focused regulatory engagement. For practitioners, the outcome of this specific case is the sole determinant of the company's immediate success in the Biotechnology & Pharmaceuticals technology area.
The busiest examiner for this portfolio is BAUER, BRIANNA LEE, who is overseeing 1 busiest examiner pending action. Because this 1 busiest examiner pending action is the only one active, the company's entire prosecution strategy is centered on the interaction with this individual. There are no other 1 distinct examiners to provide alternative perspectives or comparative results within the current workload. This requires a strategy tailored specifically to the preferences of this one official.
The involvement of only 1 distinct art unit reflects a narrow technical scope for the current filing. Without additional pending matters, the company does not have a distributed risk profile across multiple 1 distinct art units. Every resource must be directed toward resolving the 1 pending office action successfully. This singular focus makes the relationship with the 1 distinct examiner the most critical factor in the company's current patenting efforts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAUER, BRIANNA LEE | 1 | 66.7% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18706368 | GONADOTROPIN-RELEASING HORMONE ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | BAUER, BRIANNA LEE | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18706368 | GONADOTROPIN-RELEASING HORMONE ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | BAUER, BRIANNA LEE | 1623 | §103§112 | Non-Final OA | — | Pending | Apr 30, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShandong Luye Pharmaceutical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Brianna Lee Bauer has the most, with 1 of Shandong Luye Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.